Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paola Facheris

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Expert Opinion on Investigational Drugs|June 6, 2022
Current emerging and investigational drugs for the treatment of chronic hand eczemaJulia Cheng, Paola Facheris, Benjamin Ungar, et al.
Cellular & Molecular Immunology|March 17, 2023
The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatmentPaola Facheris, Jane Jeffery, Ester Del Duca, et al.
Frontiers in Immunology|April 27, 2026
Effects of tildrakizumab on circulating T cells in autoreactive psoriatic patientsPaola Facheris, Rebecca Favaro, Mario Valenti, et al.
Dermatology and Therapy|April 24, 2026
Tildrakizumab Improves Disease Severity and Patient-Reported Outcomes in Moderate-to-Severe Chronic Plaque Psoriasis: A Prospective Real-World StudyPaola Facheris, Francesco Piscazzi, Giovanni Fiorillo, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|July 13, 2023
Targeting type 2 immune activation beyond atopic dermatitisDonald Y M Leung, Paola Facheris, Karen A Veverka, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 30, 2025
Reply to Hagino et al.: 'Importance of Upadacitinib dose escalation prior to switch to lebrikizumab'Luigi Gargiulo, Matteo Bianco, Luciano Ibba, et al.
The Journal of Dermatological Treatment|August 9, 2023
Upadacitinib for the treatment of atopic dermatitis in the elderly: an Italian case series of seven patientsFrancesco Piscazzi, Luigi Gargiulo, Luciano Ibba, et al.
Dermatology Reports|July 3, 2024
Atypical facial pustular folliculitis by <i>Klebsiella pneumoniae</i>: a case reportMario Valenti, Andrea Cortese, Paola Facheris, et al.
Dermatology and Therapy|April 9, 2026
Targeting TYK2 in Cutaneous Autoimmunity: Deucravacitinib-Induced Remission of Discoid Lupus and Psoriasis with Supportive Confocal Microscopy FindingsFrancesco D'Oria, Francesco Piscazzi, Paola Facheris, et al.
The Journal of Dermatological Treatment|May 29, 2023
Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experienceLuigi Gargiulo, Luciano Ibba, Carlo Alberto Vignoli, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Expert Opinion on Investigational Drugs|June 6, 2022
Current emerging and investigational drugs for the treatment of chronic hand eczemaJulia Cheng, Paola Facheris, Benjamin Ungar, et al.
Cellular & Molecular Immunology|March 17, 2023
The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatmentPaola Facheris, Jane Jeffery, Ester Del Duca, et al.
Frontiers in Immunology|April 27, 2026
Effects of tildrakizumab on circulating T cells in autoreactive psoriatic patientsPaola Facheris, Rebecca Favaro, Mario Valenti, et al.
Dermatology and Therapy|April 24, 2026
Tildrakizumab Improves Disease Severity and Patient-Reported Outcomes in Moderate-to-Severe Chronic Plaque Psoriasis: A Prospective Real-World StudyPaola Facheris, Francesco Piscazzi, Giovanni Fiorillo, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|July 13, 2023
Targeting type 2 immune activation beyond atopic dermatitisDonald Y M Leung, Paola Facheris, Karen A Veverka, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 30, 2025
Reply to Hagino et al.: 'Importance of Upadacitinib dose escalation prior to switch to lebrikizumab'Luigi Gargiulo, Matteo Bianco, Luciano Ibba, et al.
The Journal of Dermatological Treatment|August 9, 2023
Upadacitinib for the treatment of atopic dermatitis in the elderly: an Italian case series of seven patientsFrancesco Piscazzi, Luigi Gargiulo, Luciano Ibba, et al.
Dermatology Reports|July 3, 2024
Atypical facial pustular folliculitis by <i>Klebsiella pneumoniae</i>: a case reportMario Valenti, Andrea Cortese, Paola Facheris, et al.
Dermatology and Therapy|April 9, 2026
Targeting TYK2 in Cutaneous Autoimmunity: Deucravacitinib-Induced Remission of Discoid Lupus and Psoriasis with Supportive Confocal Microscopy FindingsFrancesco D'Oria, Francesco Piscazzi, Paola Facheris, et al.
The Journal of Dermatological Treatment|May 29, 2023
Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experienceLuigi Gargiulo, Luciano Ibba, Carlo Alberto Vignoli, et al.
Pageof 6